Nektar Therapeutics (NKTR) Income from Continuing Operations (2010 - 2026)
Nektar Therapeutics (NKTR) recorded quarterly Income from Continuing Operations of 43154000.0 in Q1 2026, down 24.24% quarter-over-quarter from 34733000.0 in Q4 2025, and up 7.04% on a YoY basis from 40316612.34 in Q1 2025.
Nektar Therapeutics (NKTR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 43154000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 7.04% year-over-year to 43154000.0; the TTM figure through Mar 2026 stood at 152082000.0 (down 18.27% YoY), while the FY2025 annual figure was 155349000.0, down 30.58% from the prior year.
- Income from Continuing Operations was 43154000.0 for Q1 2026 at Nektar Therapeutics, down from 34733000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 7251000.0 in Q4 2024 to a low of 159068000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 56506470.59 across 5 years, with a median of 45837000.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 117.7% in 2024, then tumbled 579.01% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 59688000.0 in 2022, then jumped by 31.37% to 40961000.0 in 2023, then soared by 117.7% to 7251000.0 in 2024, then sank by 579.01% to 34733000.0 in 2025, then decreased by 24.24% to 43154000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 43154000.0 (Q1 2026), 34733000.0 (Q4 2025), and 34988000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Nektar Therapeutics | 1.51 Bn | 939.55 Mn | 3.16 Mn | -43.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.15 Mn |
| Dec 31, 2025 | -34.73 Mn |
| Sep 30, 2025 | -34.99 Mn |
| Jun 30, 2025 | -39.21 Mn |
| Mar 31, 2025 | -46.42 Mn |
| Dec 31, 2024 | 7.25 Mn |
| Sep 30, 2024 | -37.06 Mn |
| Jun 30, 2024 | -52.36 Mn |
| Mar 31, 2024 | -36.80 Mn |
| Dec 31, 2023 | -40.96 Mn |
| Sep 30, 2023 | -45.84 Mn |
| Jun 30, 2023 | -51.12 Mn |
| Mar 31, 2023 | -137.02 Mn |
| Dec 31, 2022 | -59.69 Mn |
| Sep 30, 2022 | -59.05 Mn |
| Jun 30, 2022 | -159.07 Mn |
| Mar 31, 2022 | -90.39 Mn |
| Dec 31, 2021 | -145.65 Mn |
| Sep 30, 2021 | -129.71 Mn |
| Jun 30, 2021 | -125.52 Mn |